Skip to content

Office of Professional Education

View Live Events

NTM Journal Club

Respiratory Medicine Updates: A Virtual Clinical Community

The 2021-2022 NTM Journal Club has concluded. Check out article summaries and recordings of the previous sessions below.

Previous NTM Journal Club Sessions:

Webinar icon
  • August 23-24, 2022
    • August 2022 Article Summary: Time to Positive Culture Detection Predicts Mycobacterium avium Pulmonary Disease Severity and Treatment Initiation. Ann Am Thorac Soc. 2022 Jun;19(6):925-932. doi: 10.1513/AnnalsATS.202107-765OC. PMID: 34851813. View here.
    • Recorded Zoom Webinar on VuMedi.
  • July 26-27, 2022
    • July 2022 Article Summary: Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases. Lancet Infect Dis. 2022 Jul;22(7):e178-e190. doi: 10.1016/S1473-3099(21)00586-7. Epub 2022 Jan 25. Erratum in: Lancet Infect Dis. 2022 Mar;22(3):e73. PMID: 35090639. View here.
    • Recorded Zoom Webinar on VuMedi.
  • June 28-29, 2022
    • June 2022 Article Summary: Host and pathogen response to bacteriophage engineered against Mycobacterium abscessus lung infection. Cell. 2022 May 26;185(11):1860-1874.e12. doi: 10.1016/j.cell.2022.04.024. Epub 2022 May 13. PMID: 35568033. View here.
    • Recorded Zoom Webinar on VuMedi.
  • May 24-25, 2022
    • May 2022 Article Summary: Genomic Analysis of a Hospital-Associated Outbreak of Mycobacterium abscessus: Implications on Transmission. J Clin Microbiol. 2022 Jan 19;60(1):e0154721. doi: 10.1128/JCM.01547-21. Epub 2021 Oct 27. PubMed PMID: 34705540; PubMed Central PMCID: PMC8769749. View here.
    • Recorded Zoom Webinar on VuMedi.

  • April 26-27, 2022
    • April 2022 Article Summary: Mycobacterium abscessus biofilms have viscoelastic properties which may contribute to their recalcitrance in chronic pulmonary infections. Sci Rep. 2021 Mar 3;11(1):5020. doi: 10.1038/s41598-021-84525-x. PMID: 33658597. View here.
    • Recorded Zoom Webinar on VuMedi.

  • March 29-30, 2022
    • March 2022 Article Summary: Pilot study to test inhaled nitric oxide in cystic fibrosis patients with refractory Mycobacterium abscessus lung infection. J Cyst Fibros. 2020 Mar;19(2):225-231. doi: 10.1016/j.jcf.2019.05.002. Epub 2019 May 23. PMID: 31129068. View here.

  • February 22-23, 2022
    • February 2022 Article Summary: Mycobacteriophage-antibiotic therapy promotes enhanced clearance of drug-resistant Mycobacterium abscessus. Matt D Johansen, Matthéo Alcaraz, Rebekah M Dedrick, Françoise Roquet-Banères, Claire Hamela, Graham F Hatfull, Laurent Kremer. s Model Mech. 2021 Sep 1;14(9):dmm049159. doi: 10.1242/dmm.049159. View here.
    • Recorded Zoom Webinar on VuMedi.

  • January 25-26, 2022
    • January 2022 Article Summary: Preliminary, Real-world, Multicenter Experience With Omadacycline for Mycobacterium abscessus Infections. Open Forum Infectious Diseases, Volume 8, Issue 2, February 2021, ofab002, View here.
    • Recorded Zoom Webinar on VuMedi.

  • November 30, 2021
    • November 2021 Article Summary: Airway Clearance Techniques in Bronchiectasis: Analysis From the United States Bronchiectasis and Non-TB Mycobacteria Research Registry. Chest, Volume 158, Issue 4, 2020, Pages 1376-1384, ISSN 0012-3692, View here.
    • Recorded Zoom Webinar on VuMedi.

  • October 26-27, 2021
    • October 2021 Article Summary: Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease: Sustainability and Durability of Culture Conversion and Safety of Long-term Exposure. Griffith DE, et al; CONVERT Study Group.Chest. 2021 Sep;160(3):831-842. DOI: 10.1016/j.chest.2021.03.070. View here.
    • Recorded Zoom Webinar on VuMedi.

  • September 28-29, 2021
    • September 2021 Article Summary: Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis, N Engl J Med 2020; 383:2127-2137, DOI: 10.1056/NEJMoa2021713. View here.
    • Recorded Zoom Webinar on VuMedi.

  • August 24-25, 2021
    • August 2021 Article Summary: Amikacin liposome inhalation suspension for Treatment-Refractory lung disease caused by Mycobacterium avium complex (CONVERT). A prospective, open-label, randomized study. Am J Repir Crit Care Med 2018; 198: 1559-1569. View here.
    • Recorded Zoom Webinar on VuMedi.

Target Audience:

Pulmonologists, Infectious Disease Physicians, Primary Care and Family Medicine Physicians, Physician Assistants, and Advanced Practice Nurses who treat patients with NTM.

Program Chairs:

Charles L Daley MD

Charles L. Daley, MD
Chief, Division of Mycobacterial and Respiratory Infections
Professor of Medicine
University of Colorado Denver
National Jewish Health
Denver, CO

Shannon H. Kasperbauer MDShannon H. Kasperbauer, MD
Associate Professor of Medicine
Division of Mycobacterial and Respiratory Infections
National Jewish Health
University of Colorado Denver
Denver, CO

Learning Objectives:

Upon completion of this activity, the participant will be better able to:

  • Apply critical thinking for research analysis in the review of new data and guidelines in NTM.
  • Utilize increased awareness and understanding of research, evidence and best practices to inform clinical practice in NTM.
  • Support an online community of practitioners to share key insights, latest research, and treatment strategies for patients with NTM.


For questions, please call the Office of Professional Education at National Jewish Health at 303.398.1000 or 800.844.2305, or email

Accreditation and Designation Statements:

The 2021-2022 NTM Journal Club has concluded. This activity is no longer available for credit.


Supported by an Educational Grant from Insmed.